Logo of Microba Life Sciences (ASX:MAP)Latest Microba Life Sciences (ASX:MAP) News

Page 1
Page 1 of 4

Genetic Signatures ends Microba merger after funding gap emerges

Genetic Signatures has abandoned its proposed merger with Microba Life Sciences after Microba said it lacked the financial capacity to complete the transaction without fresh capital. GSS also declined to provide unsecured working capital funding, leaving the shareholder vote and Takeovers Panel process to be unwound separately.
Ada Torres
18 Nov 2026

Microba suspended as merger funding falters and cash runway tightens

Microba Life Sciences has been suspended from trading after revised terms for its proposed Genetic Signatures merger left it unable to complete the second tranche of its institutional placement. The company says it is assessing alternative funding while its cashflow runway narrows.
Victor Sage
17 Nov 2026

Healthcare Wrap - Week 46 (9 Nov -> 13 Nov) 2026

EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
Logan Eniac
14 Nov 2026

Takeovers Panel challenge puts Genetic Signatures-Microba merger process under scrutiny

BCAL Diagnostics, an 18.46% shareholder of Genetic Signatures, has asked the Takeovers Panel to intervene over the proposed merger with Microba Life Sciences. The application alleges the deal structure and shareholder process lack adequate protections, although no Panel has yet been appointed and no decision has been made.
Ada Torres
13 Nov 2026

Market Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Prominence Energy doubled as hydrogen speculation drove the week’s biggest move, while takeover news lifted RAS Technology and Cleanaway.
Zip Co and several resource developers fell as investors weighed costs, capital needs and delivery risks.
Logan Eniac
24 Oct 2026

Microba raises $2.025 million as cash runway tightens and merger advances

Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
20 Oct 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

Microba Reports FY26 Results with Revenue Down 5.8%, Loss Up 38.7%, Core Testing Revenue Up 92%, and Targets Cash Flow Break-Even in 2027

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.
Ada Torres
31 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Microba Secures $5.41 Million to Boost Diagnostics Expansion and New Product Launch

Microba Life Sciences has wrapped up a $5.41 million capital raise combining a $5 million institutional Placement and a $407,500 Share Purchase Plan, strengthening its balance sheet to accelerate growth in Australia and the UK.
Ada Torres
28 July 2026

Market Wrap - Week 29 (13 July -> 17 July) 2026

Wild swings hit the ASX this week, with Janus Electric doubling, Aura sliding almost 30%, and TechGen jumping more than 22%. Big news kept landing, but many stocks still fell as early gains faded and traders locked in profits.
Logan Eniac
18 July 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026